Synonym
GW7604; GW 7604; GW-7604; (E)-GW7604
IUPAC/Chemical Name
3-{4-[1-(4-Hydroxy-phenyl)-2-phenyl-but-1-enyl]-phenyl}-acrylic acid
InChi Key
SCVIEONTACSLJA-VZBZSUMNSA-N
InChi Code
InChI=1S/C25H22O3/c1-2-23(19-6-4-3-5-7-19)25(21-13-15-22(26)16-14-21)20-11-8-18(9-12-20)10-17-24(27)28/h3-17,26H,2H2,1H3,(H,27,28)/b17-10+,25-23-
SMILES Code
O=C(O)/C=C/C1=CC=C(/C(C2=CC=C(O)C=C2)=C(C3=CC=CC=C3)\CC)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
GW7604 is an antiestrogen. GW7604 is the metabolite of GW5638, which is a high affinity estrogen receptor (ER) antagonist.
In vitro activity:
GW7604 inhibited both estradiol (10(-9) M) and 4-OHT (10(-8), 10(-7) M) induction of TGFalpha in a concentration related manner (10(-9)-10(-6) M).
Reference: Endocrinology. 2001 Feb;142(2):838-46. https://pubmed.ncbi.nlm.nih.gov/11159857/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
370.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology. 2001 Feb;142(2):838-46. doi: 10.1210/endo.142.2.7932. PMID: 11159857.
In vitro protocol:
1. Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology. 2001 Feb;142(2):838-46. doi: 10.1210/endo.142.2.7932. PMID: 11159857.
1: Levenson AS, Kliakhandler IL, Svoboda KM, Pease KM, Kaiser SA, Ward JE 3rd, Jordan VC. Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. Br J Cancer. 2002 Aug 12;87(4):449-56. PubMed PMID: 12177783; PubMed Central PMCID: PMC2376139.
2: Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review. PubMed PMID: 11584060.
3: Levenson AS, MacGregor Schafer JI, Bentrem DJ, Pease KM, Jordan VC. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):61-70. PubMed PMID: 11384864.
4: Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol. 2001 May;8(5):427-36. PubMed PMID: 11358690.
5: Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology. 2001 Feb;142(2):838-46. PubMed PMID: 11159857.
6: Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 1999 Dec;140(12):5828-40. PubMed PMID: 10579349.
